Meredith Watson
Nurse Practitioner · Columbia, SCNPI 1598115511
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 434 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,674 and has fallen 50.4% since, to $1,327 in 2025. Among nurse practitioner clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 434 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$669
- Xeris Pharmaceuticals, Inc.$663
- Insulet Corporation$491
- IBSA Pharma Inc.$455
- Abbott$417
- plus $5K from 36 others
What the payments were for
- Food & beverage$8,44698%
- Education$751%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 63 | $1,287 |
| Novo Nordisk | 31 | $669 |
| Xeris Pharmaceuticals, Inc. | 37 | $663 |
| Insulet Corporation | 23 | $491 |
| IBSA Pharma Inc. | 23 | $455 |
| Abbott | 22 | $417 |
| Sanofi-aventis U.S. LLC | 19 | $378 |
| Medtronic | 16 | $325 |
| Boehringer Ingelheim | 19 | $324 |
| AbbVie | 20 | $319 |
| Amneal Pharmaceuticals LLC | 17 | $305 |
| Amgen | 18 | $303 |
| Tandem Diabetes Care, Inc. | 12 | $245 |
| Mannkind Corporation | 10 | $213 |
| BETA Bionics, Inc. | 9 | $212 |
| Recordati_rare_diseases_inc. | 7 | $193 |
| Antares Pharma, Inc. | 12 | $177 |
| Cequr Corporation | 3 | $147 |
| Bayer | 8 | $146 |
| Ascensia Diabetes Care US Inc. | 6 | $141 |
| Lifescan, Inc. | 8 | $130 |
| Radius Health, Inc. | 6 | $119 |
| Ascendis Pharma Endocrinology Inc | 5 | $119 |
| Dexcom, Inc. | 4 | $112 |
| AstraZeneca(2 entities) | 5 | $99 |
| Corcept Therapeutics | 5 | $85 |
| Pfizer | 4 | $82 |
| Novartis | 3 | $75 |
| Sequel Med Tech, LLC | 3 | $62 |
| Zealand Pharma US, Inc. | 4 | $60 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Chiesi USA, Inc. | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Intuity Medical Inc | 1 | $23 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Amryt Pharma Holdings Ltd | 1 | $20 |
| Halozyme Inc | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Merck | 1 | $14 |
| BD | 1 | $13 |
| Embecta Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$115
How this compares
$8,580 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 289 | $408,598 |
| OzempicSemaglutide | 244 | $380,799 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 123 | $185,000 |
| Tresiba Flextouch U-200Insulin Degludec | 124 | $160,962 |
| TrulicityDulaglutide | 85 | $122,696 |
| JardianceEmpagliflozin | 82 | $105,723 |
| FarxigaDapagliflozin Propanediol | 89 | $99,346 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 27 | $69,582 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 59 | $58,164 |
| Humalog Kwikpen U-200Insulin Lispro | 26 | $52,991 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 51 | $47,058 |
| Humalog Kwikpen U-100Insulin Lispro | 151 | $46,135 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 46 | $46,032 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $32,569 |
| Novolog FlexpenInsulin Aspart | 92 | $28,021 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,287 | $546,251422 claims |
| Novo NordiskOzempic, Novolog | $669 | $385,290262 claims |
| Boehringer IngelheimJardiance, Tradjenta | $324 | $117,922104 claims |
| AstraZenecaFarxiga | $99 | $99,34689 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $378 | $58,16459 claims |
| MerckJanuvia | $14 | $18,76317 claims |
| AbbVieSynthroid | $319 | $1,72517 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $305 | $1,66777 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.
Other nurse practitioner in Columbia
- Melissa BramanteColumbia$19K
- Tonya MeltonColumbia$11K
- Andrea OatesColumbia$9K
- Kimberly WillisColumbia$8K
- Leigh DavisColumbia$7K
- David WiltGreenville$90K
- Whitney ReedCharleston$54K
- Mary JohnsonCharleston$34K
- Amanda HareCharleston$30K
- Kellie McLainCharleston$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.